Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Journal of Clinical Oncology · 01.01.2023 · 41 (1) · 22-31
DOI: 10.1200/jco.22.01643 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.01.2023. Verfasst von Christopher J Hoimes und 14 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute, Duke University, Durham, NC. Hauptthemen laut MEDLINE: Cisplatin, Neoplasms. Die Arbeit wurde bisher 281-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible. Each enfortumab vedotin and pembrolizumab have shown a survival benefit versus chemotherapy in UC, are not restricted by cisplatin eligibility, and warrant investigation as a first-line (1L) combination therapy in patients ineligible for cisplatin. METHODS In this ongoing phase Ib/II, multicenter, open-label study, 1L cisplatin-ineligible patients with la/mUC received enfortumab vedotin 1.25 mg/kg once daily on days 1 and 8 and pembrolizumab 200 mg (day 1) intravenously once daily in 3-week cycles. The primary end point was safety. Key secondary end points included confirmed objective response rate, duration of response (DOR), and overall survival (OS). RESULTS Forty-five patients received enfortumab vedotin plus pembrolizumab. The most common treatment-related adverse events (TRAEs) were peripheral sensory neuropathy (55.6%), fatigue (51.1%), and alopecia (48.9%). Twenty-nine patients (64.4%) had grade 3 or higher TRAEs; the most common were increased lipase (17.8%), maculopapular rash (11.1%), and fatigue (11.1%). One death (2.2%) was classified as a TRAE. The confirmed objective response rate after a median of nine cycles was 73.3% with a complete response rate of 15.6%. The median DOR and median OS were 25.6 months and 26.1 months, respectively. CONCLUSION Enfortumab vedotin plus pembrolizumab showed a manageable safety profile. Most patients experienced tumor shrinkage. The median DOR and median OS exceeding 2 years in a cisplatin-ineligible patient population make this a promising combination currently under investigation in a phase III study (ClinicalTrials.gov identifier: NCT04223856 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Cancer Institute, Duke University, Durham, NC.
- Seidman Cancer Center at University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH.
- University of Colorado Comprehensive Cancer Center, Aurora, CO.
- University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
- University of California San Francisco Medical Center, San Francisco, CA.
- Winship Cancer Institute of Emory University, Atlanta, GA.
ORCID-Profile: Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Shilpa Gupta, Jaime R Merchan, Rana R McKay, Daniel P Petrylak, Carolyn Sasse, Anne-Sophie Carret, Jonathan E Rosenberg
Förderung
- NCI NIH HHS
Zitieren
APA
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., Srinivas, S., Merchan, J. R., McKay, R. R., Petrylak, D. P., Sasse, C., Moreno, B. H., Yu, Y., Carret, A. S., & Rosenberg, J. E. (2023). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology, 41(1), 22-31. https://doi.org/10.1200/jco.22.01643
Vancouver
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology. 2023;41(1):22-31. doi:10.1200/jco.22.01643
BibTeX
@article{Hoimes2023,
author = {Hoimes, Christopher J and Flaig, Thomas W and Milowsky, Matthew I and Friedlander, Terence W and Bilen, Mehmet Asim and Gupta, Shilpa and Srinivas, Sandy and Merchan, Jaime R and McKay, Rana R and Petrylak, Daniel P and Sasse, Carolyn and Moreno, Blanca Homet and Yu, Yao and Carret, Anne-Sophie and Rosenberg, Jonathan E},
title = {Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {1},
pages = {22--31},
doi = {10.1200/jco.22.01643}
}
EUVIMED